A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. by Fedorov, O, Marsden, B, Pogacic, V, Rellos, P, Müller, S, Bullock, A, Schwaller, J, Sundström, M, Knapp, S

Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. by Pogacic, V, Bullock, A, Fedorov, O, Filippakopoulos, P, Gasser, C, Biondi, A, Meyer-Monard, S, Knapp, S, Schwaller, J

Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. by Grundler, R, Brault, L, Gasser, C, Bullock, A, Dechow, T, Woetzel, S, Pogacic, V, Villa, A, Ehret, S, Berridge, G, Spoo, A, Dierks, C, Biondi, A, Knapp, S, Duyster, J, Schwaller, J